Whitehawk Therapeutics (WHWK) director reports option grant and large fund holdings
Rhea-AI Filing Summary
Whitehawk Therapeutics, Inc. director Anupam Dalal reported two equity-related acquisitions. He was granted 38,040 stock options with an exercise price of $4.16 per share, expiring in 2036; all options vest on the earlier of one year from the June 12, 2026 grant date or immediately before the next annual stockholders’ meeting, subject to continued service.
Dalal also reported an indirect acquisition of 1,275,510 shares of common stock at $3.92 per share, held through Acuta Capital Fund, LP and Acuta Opportunity Fund, LP, bringing his reported indirect holdings via these funds to 4,685,912 shares. He has voting and investment authority over these fund holdings but disclaims beneficial ownership except to the extent of his pecuniary interest. Separately, he holds 1,130 common shares directly.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 1,275,510 shares
Net Buy
3 txns
Insider
Dalal Anupam
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F2 | 38,040 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 1,275,510 | $3.92 | $5.00M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 38,040 shares (Direct);
Common Stock — 4,685,912 shares (Indirect, See footnote);
Common Stock — 1,130 shares (Direct)
Footnotes (2)
- F1. Consists of (i) 3,538,288 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 1,147,624 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.
- F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Key Figures
Stock options granted: 38,040 options
Option exercise price: $4.16 per share
Indirect shares acquired: 1,275,510 shares
+3 more
6 metrics
Stock options granted
38,040 options
Stock Option (right to buy) granted to director on 2026-06-12
Option exercise price
$4.16 per share
Exercise price of options expiring 2036-06-12
Indirect shares acquired
1,275,510 shares
Common stock indirectly acquired on 2026-05-14 at $3.92 per share
Indirect holdings after transaction
4,685,912 shares
Total common shares held indirectly via Acuta Capital and Acuta Opportunity funds
Direct common shares held
1,130 shares
Directly owned common stock position following 2026-05-14 entry
Option expiration date
June 12, 2036
Expiration of 38,040 stock options granted June 12, 2026
Key Terms
Stock Option (right to buy), Service Provider, 2021 Equity Incentive Plan, pecuniary interest, +1 more
5 terms
Stock Option (right to buy) financial
"Security title reported as "Stock Option (right to buy)" for the derivative grant"
Service Provider financial
"Vesting is subject to the Reporting Person continuing to be a Service Provider"
2021 Equity Incentive Plan financial
"Defined as the Issuer's 2021 Equity Incentive Plan governing the option terms"
pecuniary interest financial
"Reporting Person disclaims beneficial ownership except to the extent of their pecuniary interest"
indirect ownership financial
"Common stock held by Acuta Capital and Acuta Opportunity Fund reported as indirect ownership"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Whitehawk Therapeutics (WHWK) director Anupam Dalal report?
Anupam Dalal reported a grant of 38,040 stock options with a $4.16 exercise price and an indirect acquisition of 1,275,510 common shares at $3.92 per share through investment funds he oversees.
What are the key terms of Anupam Dalal’s stock option grant at WHWK?
Dalal received 38,040 stock options with a $4.16 per-share exercise price, expiring on June 12, 2036. The options fully vest on the earlier of one year from the June 12, 2026 grant date or immediately before the next annual stockholders’ meeting, subject to continued service.
Under what conditions do Anupam Dalal’s WHWK options vest?
All 38,040 options vest if Dalal continues as a Service Provider until the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholders’ meeting, as defined in the 2021 Equity Incentive Plan.